UK Newspaper The Telegraph Set For US Ownership
British right-wing newspaper The Telegraph has agreed a takeover by US investment group RedBird Capital Partners, ending a two-year saga marked by UK government intervention over press freedoms.
RedBird has struck an "in-principle agreement" to purchase The Telegraph Media Group (TMG), which comprises the 170-year-old paper's print and online operations, for 500 million euros ($670 million), the pair announced in a statement on Friday.
It concludes a protracted sale that involved an intervention by the previous Conservative government.
US-Emirati consortium RedBird IMI, comprising Redbird Capital, had already struck a deal for TMG in late 2023.
However, the previous UK government triggered a swift resale amid concern over the potential impact on freedom of speech given Abu Dhabi's press censorship record.
RedBird Capital Partners on Friday said the agreement struck with TMG makes it "the sole control owner" and "unlocks a new era of growth for the title" founded in 1855.
"RedBird's growth strategy will include capital investment in digital operations, subscriptions and journalism as it looks to expand The Telegraph internationally."
The US group added it is in "discussions with select UK-based minority investors with print media expertise and strong commitment to upholding the editorial values of" the paper.
It comes after the current Labour government recently struck a trade agreement with the United States, as Prime Minister Keir Starmer enjoys cordial relations with US President Donald Trump despite the latter's tariffs blitz.
'Cultural Institution'
"We believe that the UK is a great place to invest, and this acquisition is an important part of RedBird's growing portfolio of media and entertainment companies in the UK," said RedBird's founder and managing partner, Gerry Cardinale.
As for The Telegraph, he added that RedBird has "tremendous conviction in the growth potential of this incredibly important cultural institution".
TMG chief executive Anna Jones said RedBird "will unlock" The Telegraph's "full potential".
"RedBird Capital Partners have exciting growth plans that build on our success," she added.
The US group said it will look to expand The Telegraph's global reach, particularly in the United States.
"RedBird's growth strategy will include capital investment in... digital operations to continue driving subscriptions, using best in-class data analytics and Artificial Intelligence tools," it added.
TMG last year agreed to sell British right-wing magazine The Spectator to hedge fund manager Paul Marshall for 100 million euros.
At the end of 2024, Britain's Guardian Media Group struck a deal to sell the world's oldest Sunday newspaper, The Observer, to online news company Tortoise Media.
Tortoise has carved out an online niche with in-depth reports, characterising its overall approach as not "breaking news but what's driving the news" with investigations and podcasts.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
26 minutes ago
- Hindustan Times
Techie with ‘ ₹1 crore net worth' at 25 opens up about immense stress at work: ‘Lost hair, lost weight'
A post on Reddit by a techie who claims to have built a portfolio worth ₹1 crore after working for just four years has intrigued people. In the post, the individual also opened up about the toll of success. A techie shared that he has created a portfolio of ₹ 1 crore by carefully investing his salary. (Unsplash/aksangai) The person wrote, 'I reached 1 crore net worth, across equity (Indian + US), MFs (Indian), deposits and money at hand at the age 25. It was shortly before I turned 26, but my aim was to reach that at 25. So that's a target achieved I guess.' The techie then gives a detailed account of when and how they achieved their goal. However, the person also mentioned, 'While the financial freedom spoils you. The stress from work is extremely high. Quite literally, it breaks you down. I have lost hair, lost weight, at times drank alcohol very frequently just to cope with it. In my defense, I am taking better care of myself now.' Take a look at the full post: What did social media say? An individual posted, 'You are probably not reaching 10 million from a job in India anytime soon. You will be so old that retiring early doesn't even matter (early 50s or never). You pay 40% income tax and 20% GST. First reach a million. You will understand that it is not as easy. You at least need to work for 25 years and be lucky with your portfolio.' Another posted, 'Have you thought of giving back to society or doing something purposeful with your talent and time?' The OP replied, 'Giving away money still feels hard, apart from the small stuff like tipping and all. I don't have anything planned yet. I've thought about it, though. Sponsoring someone's education or medical treatment would be the most direct way to impact someone. But there's still time in that. Maybe in a few years. I do random stuff, though. There's an Instagram account which does a lot of philanthropy for dogs (Pillu bhai and gang, if someone remembers). I've donated a couple of thousand to them. Given 3000 to Wikipedia (this is total across the last 3 years).' A third expressed, 'It would be great if you can guide a few talented folks, even if they achieve 20 LPA that will be a great deal for them.' A fourth wrote, 'Bhai itni salary me tohh mei 2 crore se jyada bana leta khair koi nhi neend raat me aati hai ki nhi???' OP responded, 'Sleep schedule is bad. I even wrote this post at 2am before going to bed. But I do get 7 hours on most days. I sleep late since my work meetings creep into evenings (sometimes till 11pm).'
&w=3840&q=100)
First Post
26 minutes ago
- First Post
Trump rules out deploying US troops in Ukraine under security guarantees
The US president, however, said that Washington is ready to provide air support to Kyiv in an attempt to play by the security guarantees deal. This would still be a major shift in his administration's policy on the conflict US President Donald Trump and Ukrainian President Volodymyr Zelenskyy walk during a meeting, amid negotiations to end the Russian war in Ukraine, at the White House in Washington, D.C., US, on Monday. Reuters File US President Donald Trump has ruled out sending troops to Ukraine as part of security guarantees agreed upon in the White House, a move that was described as a significant breakthrough by European leaders. When asked during a phone interview with Fox News whether he could assure listeners, particularly his MAGA supporters who favour an isolationist, America-first foreign policy, that the US would not deploy troops to Ukraine, Trump responded: 'You have my assurance, and I'm president.' STORY CONTINUES BELOW THIS AD He, however, said that Washington is ready to provide air support to Kyiv in an attempt to play by the security guarantees deal. This would still be a major shift in his administration's policy on the conflict. Meanwhile, Russia has warned that the deployment of Nato troops to Ukraine would be a red line in any negotiations. However, on Tuesday, Trump brushed off those concerns and expressed continued optimism about the possibility of reaching a deal with Putin. What do the security agreements entail? Ukrainian President Volodymyr Zelenskyy said that he discussed Ukraine's plans to purchase $90 billion in American weapons through European funding during his meeting with Trump and European leaders at the White House. According to a report by the Financial Times, the security guarantees include a $50bn deal to produce drones with Ukrainian companies. A document of the guarantees does not mention which weapons Kyiv intends to procure; however, Ukraine has been clear about its intentions to purchase at least 10 US-made Patriot air defence systems. The document of the security guarantees, as seen by FT, also highlights 'lasting peace shall be based not on concessions and free gifts to Putin, but on [a] strong security framework that will prevent future aggression'. It adds that recent footage aired by Russian media suggests the Kremlin is not serious about pursuing a peace deal and holds a dim view of Trump's leadership, pointing to disparaging remarks about the US president made by prominent television host Vladimir Solovyov. UK offers air support to Ukraine The head of the British armed forces is set to inform his US counterparts that the UK is willing to deploy troops to help defend Ukraine's airspace and maritime borders, but not to engage on the front lines against Russia, as planning intensifies for a post-war security arrangement. Tony Radakin, the Chief of the Defence Staff, will attend meetings at the Pentagon on Wednesday aimed at finalising what 30 nations are prepared to contribute to Ukraine's long-term security. STORY CONTINUES BELOW THIS AD With inputs from agencies
Economic Times
an hour ago
- Economic Times
Aurobindo Pharma closing in on $5.5b Zentiva buyout
Boost to Aurobindo's European footprint Live Events Change of hands (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Mumbai: Aurobindo Pharma has emerged as the frontrunner to acquire Prague-based generic drugmaker Zentiva for $5-5.5 billion (Rs 43,500-47,900 crore) from Advent International , said several people aware of the matter, underscoring the growing consolidation of pharmaceutical assets in successful, this will be the largest-ever acquisition by an Indian pharma company, both at home and abroad, trumping the $3.2-billion acquisition of Daiichi Sankyo's stake in Ranbaxy in 2014, or Biocon Biologics' $3.3 billion cash and stock buyout of the global biosimilars business of US-based is competing with US private equity firm GTCR , the other serious contender left in the fray. Both sides are engaged in intense negotiations to finalise the various commercial and operations aspects of the late last year, Advent has been engaged with advisers Goldman Sachs and boutique investment bank PJT Partners to explore exit options for Zentiva, which it acquired seven years were made to several financial investors, including TPG and pharma competitors worldwide for a potential takeover.'The competition heated up from May. The binding offers have been submitted a few weeks ago and ongoing discussions have reached an advanced stage,' said a PE executive involved in the matter. 'Price is no longer being negotiated… A formal announcement can happen in the next fortnight or a month.'Zentiva will significantly boost Aurobindo's European footprint, specifically in the east European region–Czech Republic, Romania and Slovakia—where the market is seen as fertile and steadily warming up to a raft of biosimilars, following patent expiries of big prescription brands. Besides, as most healthcare spending in eastern Europe is led by government bulk public procurement, the returns are steadier as compared to perpetual price erosion in the revenues from Europe are already the highest among all other homegrown pharma peers. For calendar 2024, Zentiva Group's revenues were 1.7 billion euros ($1.98 billion) at an ebitda of 400 million euros ($467 million). Even then, analysts are surprised at the boldness of the bet that the Hyderabad-based company is willing to take amid heightened geopolitical risks and tariff market value stands at Rs 63,684.90 crore ($7.4 billion), whereas Zentiva is privately held. According to people aware of developments, Aurobindo has already secured a $4.75-billion credit line from MUFG–the sole financier in the transaction–as a bridge loan for the transaction. The remaining $800 million will be from the company's internal and Zentiva didn't respond to queries. Advent and MUFG declined to was the first to report on the Zentiva sale last November and on Aurobindo's interest in July this origins that can be traced back to Black Eagle Pharmacy from the 15th century, Zentiva was nationalised in 1946 and has undergone several ownership changes, including one in 1998 when the management team had taken over a majority share to refocus on branded generics. A decade later, in 2009, it got acquired by Sanofi and in 2018, got carved out by Advent for $2.4 billion, a deal process that had even seen a preliminary interest from India's Torrent the years, it has diversified its presence across categories such as prescription drugs, OTC products and consumer health and food supplements as well as geographies, growing both organically and through a series of buyouts across the region. It currently operates in 30 countries and has set a goal to reach one in five people across Europe by India, Zentiva has a manufacturing site in Gujarat. In 2022, Polish firm Pol Pharma, backed by a few private equity players, was reported to have placed a $3.5-billion bid for Zentiva, but the discussions remained inconclusive as the owners were reportedly considering a public leading drugmakers such as Biocon and, more recently, Lupin, have struck separate deals with Zentiva to push their biosimilars in the European region. Aurobindo is developing a robust pipeline of biosimilars such as denosumab (Prolia) for osteoporosis as well as omalizumab (Xolair) and bevacizumab (Avastin) for multiple cancer treatments.'While pricing pressure persists in chronic therapies, the European Union (EU) remains attractive for oncology and retail segments. Ongoing investments in EU-focused capacity continue to support volume growth,' said Amey Chalke of JM EU business of Aurobindo reported 9% revenue growth in the June quarter, from a year ago, with a strong performance across major markets and is on track to cross 1 billion euros in annual revenue in FY26. Injectables grew about 20% from the year earlier, driven by shortage-led demand. Two new oncology lines are being added to meet rising needs, as per the company also received four biosimilar approvals with commercial supplies initiated in the UK and full ramp-up expected in the third or fourth quarter of this fiscal. Aurobindo is targeting 40–60% margins in the EU biosimilar segment and aims for a blended 50% gross margin. Inhouse manufacturing now exceeds half the total formulations volumes, thereby boosting margins, inching toward 20% Aurobindo's FY25 consolidated sales of Rs 31,724 crore ($3.6 billion), the US market accounted for Rs 14,186 crore, up 6.8% from the year earlier. The European business grew 16.6% to Rs 8,356 month, Aurobindo acquired US-based contract development and manufacturing organization (CDMO) player Lannett for $250 million to shore up its manufacturing presence in the US while enhancing its capabilities in manufacturing complex generic drugs such as controlled at least three previous occasions, Aurobindo has either lost out to rivals or had to back out of marque transactions after announcing them. In 2020, it had to call off its deal to acquire the oral solids and dermatology business of Sandoz (part of Novartis) in the US for $900 million, failing to receive due approvals from US Federal Trade Commission even after two years.
